In summary, our research highlights that the Wnt/β-catenin/c-MYC/ASS1 signaling pathway serves a key role in EVO-driven suppression of CRC, validated through In vitro and In vivo studies. The gene discussed is MYC; the disease is colorectal carcinoma.